Pazopanib is active in refractory soft-tissue sarcoma (STS) and significantly prolongs PFS. Prior studies of combinations of metronomic topotecan with pazopanib have indicated preclinical evidence of response in patients with sarcoma.
This prospective, single arm, phase II study evaluated the efficacy of the combination of pazopanib with topotecan in patients with metastatic or unresectable non-adipocytic STS. Furthermore, it incorporated exploratory arms for osteosarcoma and liposarcoma. The primary endpoint was progression-free rate at 12 weeks in the non-adipocytic STS cohort.
57.5% of patients in the non-adipocytic STS cohort were progression free at 12 weeks, which did not meet the primary endpoint of the study (66%). The exploratory osteosarcoma cohort exceeded previously established phase II trial comparator data benchmark of 12% with a PFR at 12 weeks of 69.55%. Treatment with the combination of pazopanib and topotecan was accompanied by a grade 3 or 4 toxicities in most patients.
In this prospective trial in refractory metastatic or unresectable STS and osteosarcoma, the combination of pazopanib with topotecan did not meet its primary endpoint of progression-free rate at 12 weeks. The combination of pazopanib with topotecan was associated with a high degree of toxicity.
Subscribe to Journal
Get full journal access for 1 year
only $16.63 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Clark, M. A., Fisher, C., Judson, I. & Meirion Thomas, J. Soft-tissue sarcomas in adults. N. Engl. J. Med. 353, 701–711 (2005).
Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 70, 7–30 (2020).
Benjamin, R. S. & George, S. Soft Tissue Sarcoma Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Canc. Netw. 16, 536–563 (2018).
Judson, I., Verweij, J., Gelderblom, H., Hartmann, J. T., Schöffski, P., Blay, J. Y. et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 15, 415–423 (2014).
Van Glabbeke, M., van Oosterom, A. T., Oosterhuis, J. W., Mouridsen, H., Crowther, D., Somers, R. et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens–a European Organization for Research and Treatment of Cancer Soft Tissue and Bone. J. Clin. Oncol. 17, 150–157 (1999).
Verweij, J., Casali, P. G., Zalcberg, J., LeCesne, A., Reichardt, P., Blay, J.-Y. et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364, 1127–1134 (2004).
Demetri, G. D., Von Mehren, M., Jones, R. L., Hensley, M. L., Schuetze, S. M., Staddon, A. et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J. Clin. Oncol. 34, 786–793 (2016).
Folkman, J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29, asonc02906q0015 (2002).
Ferrara, N., Gerber, H.-P. & LeCouter, J. The biology of VEGF and its receptors. Nat. Med. 9, 669–676 (2003).
Van Der Graaf, W. T. A., Blay, J. Y., Chawla, S. P., Kim, D. W., Bui-Nguyen, B., Casali, P. G. et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379, 1879–1886 (2012).
Grünwald, V., Karch, A., Schuler, M., Schöffski, P., Kopp, H.-G., Bauer, S. et al. Randomized comparison of pazopanib and doxorubicin as first-line treatment in patients with metastatic soft tissue sarcoma age 60 years or older: results of a German Intergroup Study. J. Clin. Oncol. 38, 3555–3564 (2020).
Schmoll, H.-J., Lindner, L. H., Reichardt, P., Heißner, K., Kopp, H.-G., Kessler, T. et al. Efficacy of pazopanib with or without gemcitabine in patients with anthracycline- and/or ifosfamide-refractory soft tissue sarcoma. JAMA Oncol. 7, 255 (2021).
Miller, D. S., Blessing, J. A., Kilgore, L. C., Mannel, R. & Van Le, L. Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas. Am. J. Clin. Oncol. 23, 355–357 (2000).
Reichardt, P., Oechsle, K., Pink, D., Bokemeyer, C., Schneller, F., Issels, R. et al. An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma. Invest. New Drugs 21, 481–486 (2003).
Saylors, R. L., Stine, K. C., Sullivan, J., Kepner, J. L., Wall, D. A., Bernstein, M. L. et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group Phase II Study. J. Clin. Oncol. 19, 3463–3469 (2001).
Kumar, S., Mokhtari, R. B., Sheikh, R., Wu, B., Zhang, L., Xu, P. et al. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clin. Cancer Res. 17, 5656–5667 (2011).
Hashimoto, K., Man, S., Xu, P., Cruz-Munoz, W., Tang, T., Kumar, R. et al. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol. Cancer Ther. 9, 996–1006 (2010).
Kerklaan, B. M., Lolkema, M. P. J., Devriese, L. A., Voest, E. E., Nol-Boekel, A., Mergui-Roelvink, M. et al. Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours. Br. J. Cancer 113, 706–715 (2015).
Schöffski, P., Chawla, S., Maki, R. G., Italiano, A., Gelderblom, H., Choy, E. et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 387, 1629–1637 (2016).
Lagmay, J. P., Krailo, M. D., Dang, H., Kim, A., Hawkins, D. S., Beaty, O. et al. Outcome of patients with recurrent osteosarcoma enrolled in seven Phase II trials through children’s cancer group, Pediatric Oncology Group, and Children’s Oncology Group: Learning From the Past to Move Forward. J. Clin. Oncol. 34, 3031–3038 (2016).
Duffaud, F., Mir, O., Boudou-Rouquette, P., Piperno-Neumann, S., Penel, N., Bompas, E. et al. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 20, 120–133 (2019).
Italiano, A., Mir, O., Mathoulin-Pelissier, S., Penel, N., Piperno-Neumann, S., Bompas, E. et al. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 21, 446–455 (2020).
Smeland, S., Bielack, S. S., Whelan, J., Bernstein, M., Hogendoorn, P., Krailo, M. D. et al. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. Eur. J. Cancer 109, 36–50 (2019).
Mirabello, L., Troisi, R. J. & Savage, S. A. Osteosarcoma incidence and survival rates from 1973 to 2004. Cancer 115, 1531–1543 (2009).
Gaspar, N., Sirvent, F. J. B., Venkatramani, R., Longhi, A., Lervat, C., Casanova, M. et al. Phase I combination dose-finding/phase II expansion cohorts of lenvatinib + etoposide + ifosfamide in patients (pts) aged 2 to ≤ 25 years with relapsed/refractory (r/r) osteosarcoma. Ann. Oncol. 30, v688 (2019).
We are indebted to all the patients, and co-investigators who have participated in this trial. We want to thank the following collaborators of their assistance in preparation, and funding of this project.
Ethics approval and consent to participate
This study was conducted in accordance with the Declaration of Helsinki and was approved by the institutional review board of each participating institution—Northwestern University, University of Iowa, Mayo Clinic, Medical College of Wisconsin and Washington University School of Medicine. Furthermore, written consent was obtained from all participants.
Consent to publish
All data are available upon request.
The authors declare no competing interests.
Research was sponsored by Northwestern University, with limited collaborative support from Novartis Pharmaceuticals.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Schulte, B., Mohindra, N., Milhem, M. et al. Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas. Br J Cancer (2021). https://doi.org/10.1038/s41416-021-01448-0